Skip to main content
DFTX logo

Definium Therapeutics, Inc. (DFTX) Stock: Price, Forecast & Analyst Target

Definium Therapeutics, Inc. (DFTX) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $29.48 (+1.24%), as of the Nov 19, 2026 trading session; market cap $4.04B. Expected results Feb 25, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$29.48 +$0.36 (+1.24%) Market Cap $4.04B

Definium Therapeutics, Inc. · DFTX · NASDAQ · Healthcare · Biotechnology

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.

Price as of Nov 19, 2026

Key Statistics

57 of 100

MoonshotScore v2 · Definium Therapeutics (DFTX)

Fair
Business Quality Average (41)
Financial Safety Sound (79)
Valuation Full (53)
Growth Durability Shrinking (6)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Sound; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.

  • EPS beat 2 of the last 8 reports
  • Altman Z 21.68 · Piotroski F 3
  • ROE -54.0% · ROA -31.4% · current ratio 15.53 · earnings yield -7.9% · free-cash-flow yield -4.4%

Holding back: soft growth

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DFTX (57 recorded, newest six shown)
RecordedScoreBand
60Fair
61Fair
59Fair
59Fair
57Fair
57Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$29.48
Change on the day+1.24%
52-week range$10.46–$49.70
Market capitalisation$4.04B—
Shares traded on the day3.07M
Beta (volatility vs the S&P 500)2.21

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $11, high $47, latest $29. 4 reported quarters marked, 1 above and 3 below the recorded estimate. $47 $11 high $47 Feb 26, 2026 · Earnings results · reported below the recorded estimate · close $171May 7, 2026 · Earnings results · reported below the recorded estimate · close $222Aug 6, 2026 · Earnings results · reported below the recorded estimate · close $463Nov 9, 2026 · Earnings results · reported above the recorded estimate · close $334 Oct 17, 2025 Nov 19, 2026 · $29 $14Oct 17, 2025$14Oct 31, 2025$11Nov 14, 2025$13Nov 28, 2025$13Dec 12, 2025$13Dec 26, 2025$14Jan 9, 2026$17Jan 23, 2026$17Feb 6, 2026$17Feb 20, 2026$18Mar 6, 2026$18Mar 20, 2026$21Apr 2, 2026$23Apr 17, 2026$22May 1, 2026$21May 15, 2026$24May 29, 2026$25Jun 12, 2026$45Jun 26, 2026$47Jul 10, 2026$43Jul 24, 2026$46Aug 7, 2026$45Aug 21, 2026$38Sep 4, 2026$39Sep 18, 2026$37Oct 2, 2026$32Oct 16, 2026$36Oct 30, 2026$32Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Definium Therapeutics (DFTX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Moderate
Valuation Neutral
Growth Durability Negative
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Definium Therapeutics (DFTX), and what does it report?

Short answer

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Definium Therapeutics, Inc. (DFTX) is listed on NASDAQ. Definium Therapeutics, Inc. (DFTX) is classified as Healthcare / Biotechnology. SEC filing business address: ONE World Trade Center, Suite 8500, NEW York, NY, 10007. It employs 106 people and is led by Robert Barrow. The market values it at $4.04B.

2 · Latest results

What do the latest results show for Definium Therapeutics (DFTX)?

Short answer · as of

Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · EPS vs estimate
Above estimate Nov 9, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 9, 2026Not availableNot available−$0.4600−$0.5629
Aug 6, 2026Not availableNot available−$1.4400−$0.5410
May 7, 2026Not availableNot available−$0.7100−$0.4700
Feb 26, 2026Not availableNot available−$0.5100−$0.4837
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

3 · Financial strengths and risks

What are the financial strengths and risks for Definium Therapeutics (DFTX)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 21.68 · Piotroski F 3. Trailing ratios: ROE -54.0% · ROA -31.4% · current ratio 15.53 · earnings yield -7.9% · free-cash-flow yield -4.4%.

Data-derived red flags

  • Negative return on equity (-54.0%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Definium Therapeutics (DFTX)?

Short answer · as of

The next earnings report is expected on Feb 25, 2027. The number it tests is the $-2.97 EPS analysts carry for it. Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.97 · 0 analysts. Current published price targets run low $52.00 · high $79.00 · consensus $67.45 · median $68.00 against a quoted price of $29.48 (as of Nov 19, 2026).

What the records here don't tell us

  • No quarterly income statement is held for DFTX.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Definium Therapeutics compare with its peers?

Short answer

Definium Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ADMA Biologics, Inc. (ADMA) Same industry, near in market value$13.56 Nov 18, 2026$3.01B97 5-pillar Nov 18, 2026
Vericel Corporation (VCEL) Same industry, near in market value$58.26 Nov 19, 2026$2.97B95 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$27.61 Nov 18, 2026$3.49B89 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$41.17 Nov 19, 2026$4.51B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Named competitor$47.40 Nov 19, 2026$1.41B76 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$46.41 Nov 19, 2026$3.42B72 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.83 Nov 18, 2026$3.08B68 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$14.22 Nov 19, 2026$4.99B67 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.20 Nov 19, 2026$3.37B66 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.39 Nov 19, 2026$5.25B66 5-pillar Nov 18, 2026
Definium Therapeutics (DFTX) — this page$29.48$4.04B57

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$52.00 – $79.00
Consensus target
$67.45
Median target
$68.00
Revenue estimate
$0.00
EPS estimate
$-2.97

Consensus record · Captured .

Measured against a quoted price of $29.48 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 25, 2026

Transactions
43
Identified insiders
11
Purchases
0
Sales
11
Other transactions
32

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DFTX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20260%$0Sold out (was $16.77M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Definium Therapeutics (DFTX)?

Read these with our analysis →

DFTX Healthcare Stock FAQ

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for DFTX?

DFTX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is DFTX a good stock to buy?

Stock Expert AI does not rate DFTX buy, sell or hold. Definium Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the DFTX stock price today?

The last price recorded for Definium Therapeutics, Inc. (DFTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DFTX price target?

The analyst consensus price target for Definium Therapeutics, Inc. (DFTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the key factors to evaluate for DFTX?

Definium Therapeutics, Inc. (DFTX) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend yield reflects the company's focus on reinvesting earnings into research and development. Not financial advice.

How frequently does DFTX data refresh on this page?

DFTX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven DFTX's recent stock price performance?

Definium Therapeutics, Inc. (DFTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel product candidates targeting unmet needs in brain health. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider DFTX overvalued or undervalued right now?

Definium Therapeutics, Inc. (DFTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of DFTX?

Fractional-share availability for Definium Therapeutics, Inc. (DFTX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 38 figures on this page — 1 from SEC filings and earnings calls, 28 from Financial Modeling Prep (FMP), 7 with no recorded source, 1 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.